Core Viewpoint - Green Leaf Pharmaceutical (02186) saw a nearly 3% increase in stock price, currently at HKD 3.09, with a trading volume of HKD 8.3751 million, following the announcement of five new products being included in the National Medical Insurance Catalog for 2025 and the Commercial Health Insurance Innovative Drug Catalog for 2025 [1] Group 1 - Five new products from Green Leaf Pharmaceutical have been successfully included in the National Medical Insurance Catalog and the Commercial Health Insurance Innovative Drug Catalog for 2025 [1] - The new products include: - Mimesin (Oxycodone Naloxone Extended-Release Tablets) and Ruibailai (Paliperidone Palmitate Injection (II)) which are newly included in the National Medical Insurance Catalog [1] - Zanbija (Injectable Lurbinectedin) which has been successfully included in the Commercial Health Insurance Innovative Drug Catalog [1] - Baituowei (Injectable Goserelin Microspheres) and Ruiketuo (Injectable Risperidone Microspheres (II)) which have successfully renewed their inclusion in the National Medical Insurance Catalog [1]
绿叶制药涨近3% 米美欣 等五款新品获纳入国家医保药品目录或商保创新药目录